Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Back to filter
Show all topics (10)
Related topics
Download today your IsoPlexis e-book: understanding immune Cell Function In Cancer
Dec 1, 2021
Understanding complex immune-cancer interactions is critical to identifying therapeutic targets, devising novel avenues...
Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer
Nov 29, 2021
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
IsoPlexis technology: accelerating decisions in immunotherapy with predictive single-cell response
Nov 26, 2021
The IsoLight is a hub for comprehensive functional profiling of each cell type across a large assay menu of single-cell...
Accelerating AML Research Through Single-cell Multi-omics- integrate seamlessly into existing NGS
Nov 25, 2021
Dr. Linde Miles Memorial Sloan Kettering Cancer Center about her research, use of the Tapestri as a single-cell...
Discover the advanced Detector Technology in Agilent NovoCyte flow cytometers
Nov 18, 2021
This technical overview describes advancements in detector technology, and highlights examples where optimal signal...
Introducing isoLight system - Automated Cellular Proteomics hub
Nov 16, 2021
The IsoLight is a hub for comprehensive functional profiling of each cell type across a large assay menu of single-cell...
Introducing Cytek NEW 25-Color Immunoprofiling Assay & Kit!
Nov 15, 2021
To unleash the power of the Cytek full spectrum cytometry system, Cytek scientists designed and developed the 25-Color...
WEBINAR: Recent Advancements In Neurodegenerative Biomarkers
Sep 6, 2021
Recent Advancements in Neurodegenerative Biomarkers: Progress Towards a Diagnostic Blood Test for Alzheimer’s Disease
How to Improve Your Viral Nucleic Acid Extraction Processes
Sep 6, 2021
High-Throughput Extraction with CyBio FeliX
Introducing New Aura 4.0 software
Aug 31, 2021
With new features for both acquisition & analysis Aura Software enables you to capture and analyze your data quickly,...
Red-shifted firefly luciferase optimized for Candida albicans in vivo bioluminescence imaging
Sep 15, 2017
The authors of this study attempted to compare the performance of BLI in the present study with that published using the systemic infection model and light detection in the region of the kidneys. They estimated that a lower limit of detection for BLI (50 photon/s/mm2) corresponded to of about 200 CFU/kidney with the instrumentation used here (in-vivo Xtreme II). Given numbers published by Jacobsen et al. (2014) (100 photon/s/mm2 for 3,600 CFU/kidney), this suggests that the method used here increases at least by 4- to 8-fold the sensitivity of C. albicans detection.
This performance can be attributed to several factors including (i) the type of luciferase used (Mut2 has better tissue penetration capacities than the wild type luciferase) and (ii) technical differences provided by the luminescence acquisition of instruments. This performance is even more remarkable when taking in account that BLI data was collected here from animals contained in Sealed Optical Imaging Trays, which may create another obstacle of emitted light to the high sensitivity camera.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Brand profile
